GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus

Completed

Conditions studied: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

In brief

This study is conducted in Asia, Europe and in the United States of America. The aim of this study is to examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens.

Key facts

Study ID

NCT01950650

Run by

Novo Nordisk A/S

People needed

1800

Starts

2010-03-01

Expected to finish

2010-09-01

Last updated by the study team

2017-04-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• PATIENTS WITH DIABETES:
• Age 18 years or older
• Treated with insulin
• Type 1 or Type 2 diabetes
• PHYSICIANS:
• In practice for more than 1 year since completing residency
• See a minimum number of patients with diabetes per week (primary care physicians 5, specialists 10)
• Initiate insulin treatment for patients with diabetes

Where it is running

• Novo Nordisk Investigational Site — Princeton, New Jersey, United States
• Novo Nordisk Investigational Site — Beijing, Beijing Municipality, China
• Novo Nordisk Investigational Site — Paris La Défense Cedex, France
• Novo Nordisk Investigational Site — Mainz, Germany
• Novo Nordisk Investigational Site — Bangalore, India
• Novo Nordisk Investigational Site — Tokyo, Japan
• Novo Nordisk Investigational Site — Moscow, Russia
• Novo Nordisk Investigational Site — Madrid, Spain
• Novo Nordisk Investigational Site — Istanbul, Turkey (Türkiye)
• Novo Nordisk Investigational Site — Crawley, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.